targetId
stringlengths
15
15
diseaseId
stringlengths
9
15
nctid
stringlengths
11
11
clinicalStatus
stringclasses
9 values
clinicalPhase
int64
0
4
studyStartDate
stringlengths
10
10
stopStatus
stringclasses
3 values
isStopped
stringclasses
1 value
phase4
stringclasses
1 value
phase3
stringclasses
1 value
phase2
stringclasses
1 value
id
int64
0
1,709B
why_stopped
stringlengths
2
254
phase
stringclasses
7 values
start_date
stringlengths
10
10
status
stringclasses
3 values
last_update_posted_date
stringlengths
10
10
completion_date
stringlengths
10
10
prediction
stringclasses
15 values
metaprediction
stringclasses
6 values
max_l2g
float64
0.05
0.9
l2g_075
stringclasses
1 value
l2g_05
stringclasses
1 value
l2g_025
stringclasses
1 value
l2g_01
stringclasses
1 value
l2g_005
stringclasses
1 value
taId
stringclasses
23 values
taLabel
stringclasses
24 values
taLabelSimple
stringclasses
2 values
gc
float64
0
5
lof_tolerance
stringclasses
2 values
rnaDistribution
stringclasses
5 values
rnaSpecificity
stringclasses
5 values
partnersBin
stringclasses
4 values
datasourceId
stringclasses
22 values
datatypeId
stringclasses
7 values
total
int64
413k
413k
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT03236428
Active, not recruiting
2
2017-11-24
null
null
null
null
Phase II+
1,082,331,760,593
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
3
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
chembl
known_drug
413,311
ENSG00000004468
EFO_0000203
NCT04614558
Recruiting
2
2021-06-08
null
null
null
null
Phase II+
1,065,151,891,406
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0005803
hematologic disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
none
europepmc
literature
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
2
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT00699036
Unknown status
2
2007-04-01
null
null
null
null
Phase II+
120,259,084,622
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
2
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000004779
EFO_1001249
NCT04972396
Recruiting
1
2021-10-05
null
null
null
null
null
343,597,383,747
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0010282
gastrointestinal disease
Other
null
null
Detected in all
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT02406066
Completed
1
2015-03-01
null
null
null
null
null
824,633,722,293
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00802412
Completed
2
2009-01-01
null
null
null
null
Phase II+
893,353,198,669
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00208858
Completed
2
2004-12-01
null
null
null
null
Phase II+
1,185,410,975,178
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT03813121
Completed
1
2019-06-01
null
null
null
null
null
1,365,799,601,280
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT01182766
Active, not recruiting
2
2011-09-01
null
null
null
null
Phase II+
1,374,389,536,597
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
2
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000011677
EFO_0003768
NCT00755716
Completed
3
2006-04-01
null
null
null
Phase III+
Phase II+
1,382,979,470,922
null
null
null
null
null
null
null
null
null
null
null
null
null
null
EFO_0000618
nervous system disease
Other
null
LoF tolerant
Detected in some
Group enriched
none
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
1
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
null
null
4
null
null
null
Phase IV
Phase III+
Phase II+
1,597,727,834,458
null
null
null
null
null
null
null
null
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
1
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000012779
EFO_0002609
NCT00637780
Terminated
4
2010-06-01
Terminated
stopped
Phase IV
Phase III+
Phase II+
618,475,292,173
Study terminated on 13 April 2016 for business reasons. No safety and/or efficacy concerns contributed to the termination of the study
Phase 4
30/06/2010
Terminated
23/02/2017
31/01/2014
Business_Administrative
Business_Administrative
null
null
null
null
null
null
OTAR_0000006
musculoskeletal or connective tissue disease
Other
null
LoF tolerant
Detected in many
Tissue enhanced
greaterThan20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
EFO_1002001
NCT01238211
Active, not recruiting
2
2010-12-14
null
null
null
null
Phase II+
523,986,011,570
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00003204
Completed
3
1998-03-01
null
null
null
Phase III+
Phase II+
292,057,776,621
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00510887
Terminated
2
2007-01-01
Terminated
stopped
null
null
Phase II+
352,187,319,161
Low accrual.
Phase 2
31/01/2007
Terminated
12/05/2014
30/09/2013
Insufficient_Enrollment
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02348216
Active, not recruiting
1
2015-04-21
null
null
null
null
null
377,957,122,485
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00169208
Completed
2
2001-04-01
null
null
null
null
Phase II+
609,885,357,182
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00924326
Completed
1
2009-02-17
null
null
null
null
null
755,914,245,467
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01321541
Completed
3
2011-04-20
null
null
null
Phase III+
Phase II+
876,173,329,055
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT02295722
Unknown status
1
2015-04-01
null
null
null
null
null
42,949,674,404
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00110071
Completed
1
2005-01-01
null
null
null
null
null
77,309,411,723
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00119392
Completed
2
2004-06-01
null
null
null
null
Phase II+
240,518,169,289
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01529827
Completed
2
2012-02-28
null
null
null
null
Phase II+
317,827,580,785
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00562965
Terminated
3
2007-11-01
Terminated
stopped
null
Phase III+
Phase II+
369,367,188,591
See termination reason in detailed description.
Phase 3
30/11/2007
Terminated
09/01/2018
30/04/2011
No_Context
Neutral
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00079443
Terminated
2
2004-01-01
Terminated
stopped
null
null
Phase II+
412,316,861,764
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT01303887
Unknown status
3
2009-10-01
null
null
null
Phase III+
Phase II+
601,295,421,934
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00393107
Completed
2
2000-03-01
null
null
null
null
Phase II+
953,482,741,355
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03019640
Completed
2
2017-10-10
null
null
null
null
Phase II+
970,662,610,863
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00140569
Completed
3
1994-01-01
null
null
null
Phase III+
Phase II+
1,099,511,629,558
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03128359
Active, not recruiting
2
2017-05-30
null
null
null
null
Phase II+
1,357,209,666,455
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT00850499
Terminated
2
2009-09-01
Terminated
stopped
null
null
Phase II+
1,425,929,143,471
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
null
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311
ENSG00000014138
MONDO_0018906
NCT03105336
Active, not recruiting
2
2017-06-20
null
null
null
null
Phase II+
1,606,317,770,278
null
null
null
null
null
null
null
null
null
null
null
null
null
null
MONDO_0045024
cell proliferation disorder
Oncology
2
LoF tolerant
Detected in all
Low tissue specificity
from11to20
chembl
known_drug
413,311